Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Impact Sells Rights for Two PARP Inhibitors to Eikon Therapeutics

publication date: Jun 1, 2023

Shanghai’s Impact Therapeutics out-licensed global rights (ex-China) for two PARP inhibitors to Eikon Therapeutics, a San Francisco biopharma that has raised $600 million to develop novel oncology drugs. Impact is building a portfolio of cancer drugs based on the concept of synthetic lethality, which aims to take advantage of cancer cells’ genomic instability. Eikon will have rights to IMP1734, a selective PARP inhibitor of cancer cells that is expected to start clinical trials in 2H23, and another PARP inhibitor, probably IMP4297, currently in Phase II/III trials for ovarian and other solid tumor cancers. Financial details were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here